Login to Your Account


Transgene seeks new taker for TG4010 as Novartis opts out

By Cormac Sheridan
Staff Writer

Wednesday, April 30, 2014
Shares in Transgene SA dropped 15 percent Tuesday as Novartis AG decided not to trigger an option on its therapeutic vaccine TG4010, which is currently undergoing a phase IIb/III trial in non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription